Increasing testing frequency or altering strain-detection criteria didn’t improve the subclinical doxorubicin cardiotoxicity diagnostic yield in a cohort of patients with breast cancer.
First Look
No Gains From Escalating Chemo Cardiotoxicity Echo-Strain Tests
